TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35619542

Group type: EXPERIMENTAL
Intervention: Health care support
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Friends/family support
Number of subjects: 196
Study: 35619611

Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation (TTEN) for 4 weeks, daily 20 min sessions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation (TTEN)
Number of subjects: 12
Study: 35620522

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (500 mg, 2×/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 35621203

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure quartiles in early 40s
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Linear regression analyses
Number of subjects: 2591
Study: 35622006

Group type: EXPERIMENTAL
Intervention: Hospitalization for Hirschsprung disease (HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of hospitalization for HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pull-through procedures in neonatal age group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital mortality rate for HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) for HD hospitalization
Number of subjects: 0
Study: 35622074

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody) combined with hyper-CVAD regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofatumumab (anti-CD20 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (anti-CD22 monoclonal antibody)
Number of subjects: 0
Study: 35622082

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme medication (Creon)
Number of subjects: 11
Study: 35622315

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W)
Number of subjects: 22
Study: 35622394

Group type: EXPERIMENTAL
Intervention: Digital behavior change intervention combining PSD principles and BCTs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Week Plan, My Overview, Knowledge and Skills, Virtual Coach and Smart Feedback System
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Implementation of PSD principles such as tailoring, personalization, self-monitoring, reminders, rewards, rehearsal, praise, and suggestions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BCTs from clusters of goals and planning, feedback and monitoring, social support, repetition and substitution, shaping knowledge, natural consequences, associations, antecedents, identity, and self-belief
Number of subjects: 45
Study: 35622434

Group type: EXPERIMENTAL
Intervention: GI involvement in hospitalized children with acute COVID-19 or MIS-C
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: MIS-C patients with GI involvement
Number of subjects: 789
Study: 35622535

Group type: EXPERIMENTAL
Intervention: Chloramphenicol ocular ointment
Number of subjects: 527

Group type: COMPARATOR
Intervention: Fusidic acid ocular gels
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Chloramphenicol-clotrimazole
Number of subjects: 527

Group type: COMPARATOR
Intervention: Chloramphenicol-placebo
Number of subjects: 527
Study: 35623069

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers (PD-L1, MSI-H, EBV, TMB)
Number of subjects: 0
Study: 35623341

Group type: EXPERIMENTAL
Intervention: 10 regimens targeting diverse biology
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Reclassification and improved patient selection
Number of subjects: 990
Study: 35623759

Group type: EXPERIMENTAL
Intervention: Carer eSupport (internet-based intervention)
Number of subjects: 0
Study: 35623833

Group type: EXPERIMENTAL
Intervention: 3-weeks-567-kcal-hospital-controlled-VLCD
Number of subjects: 22
Study: 35623838

Group type: EXPERIMENTAL
Intervention: Skinfold thickness (SFT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Pre-pregnancy body mass index (pBMI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 181
Study: 35623855

Group type: EXPERIMENTAL
Intervention: Iron deficiency (SF < 15.0 μg/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Iron insufficiency (SF < 20.0 μg/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Iron insufficiency (SF < 25.0 μg/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA) (Hb < 12.0 g/dL and SF < 15.0 μg/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Anemia (Hb < 12.0 g/dL)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 8.0 g/dL)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP > 5.0 mg/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Alpha-1 acid glycoprotein (AGP > 1.0 g/L)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency (rural vs. urban)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Prevalence of iron insufficiency (rural vs. urban)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency anemia (IDA) (rural vs. urban)
Number of subjects: 979
Study: 35623864

Group type: EXPERIMENTAL
Intervention: Nutrition education + Refined white sugar
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nutrition education + Minimally Refined Brown Sugar
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 105
Study: 35623976

Group type: EXPERIMENTAL
Intervention: Information and therapy guides
Number of subjects: 132
Study: 35624056

Group type: EXPERIMENTAL
Intervention: Oral combination of VTS-Aspirin and ketamine (mean ketamine dose 37.8 mg, range 24 mg to 50 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral combination of VTS-Aspirin and ketamine
Number of subjects: 25
Study: 35624401

Group type: EXPERIMENTAL
Intervention: Transoral neuromuscular electrical stimulation (NMES) device
Number of subjects: 65
Study: 35624405

Group type: EXPERIMENTAL
Intervention: Micrographia writing test in PD patients
Number of subjects: 226

Group type: COMPARATOR
Intervention: Micrographia writing test in ET patients
Number of subjects: 226

Group type: COMPARATOR
Intervention: Micrographia writing test in healthy controls
Number of subjects: 226
Study: 35624418

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine at a dose of 0.5 μg/kg, adjusted in 0.1 μg/kg gradients based on previous patient outcomes.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clonidine (not specified in the trial but mentioned as a comparison).
Number of subjects: 20
Study: 35624436

Group type: EXPERIMENTAL
Intervention: Implementation of the Helsinki Declaration on Patient Safety in Anesthesiology
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Quality of work with application of the Helsinki Declaration
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Mandatory perioperative monitoring
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Use of clinical protocols for massive bleeding
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Use of clinical protocols for infection control
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Awareness of the WHO Safe Surgery checklist
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Use of checklists for equipment inspection
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Record keeping of anesthesia complications
Number of subjects: 210
Study: 35624438

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity and its risk gene polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genes and environment interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence of precocious puberty
Number of subjects: 0
Study: 35624443

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic decompression
Number of subjects: 600

Group type: COMPARATOR
Intervention: Open decompression and fusion
Number of subjects: 600
Study: 35624489

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 10
Study: 35625006

Group type: EXPERIMENTAL
Intervention: Hippotherapy (4 weeks/18 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional neurorehabilitation alone (22 weeks)
Number of subjects: 0
Study: 35625330

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS, accelerated Q-SRP within 24 h)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling with chlorhexidine-based disinfection (FMD)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: FMD with adjuvant erythritol air polishing (FMDAP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Quadrant/week-wise debridement (Q-SRP)
Number of subjects: 105
Study: 35626701

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human immature dental pulp stem cells (hIDPSC)
Number of subjects: 0
Study: 35626772

Group type: EXPERIMENTAL
Intervention: Acute physical activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic physical activity (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35627467

Group type: EXPERIMENTAL
Intervention: Three co-wear criteria of varying stringency
Number of subjects: 0
Study: 35627709

Group type: EXPERIMENTAL
Intervention: Non-paroxysmal AF
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Use of oral anticoagulants
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Use of antiarrhythmic and diuretic agents
Number of subjects: 2160
Study: 35627958

Group type: EXPERIMENTAL
Intervention: Endurance training for three months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance-strength training for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35628588

Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles (EVs) from people with diabetes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proteomic and phosphoproteomic analysis of EVs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phosphosite-centric analyses using directPA and PhosR software
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Liver-specific markers in EVs
Number of subjects: 30
Study: 35628832

Group type: EXPERIMENTAL
Intervention: Chronic OAC (various types including rivaroxaban, dabigatran, apixaban, and vitamin K antagonists)
Number of subjects: 3109

Group type: COMPARATOR
Intervention: No OAC
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Non-VKA OACs (NOACs)
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Chronic OAC (general)
Number of subjects: 3109
Study: 35628896

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH) at FiO2 15% (≈ 2500 m simulated altitude)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH) at 2500 m
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 21
Study: 35628955

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 15
Study: 35629011

Group type: EXPERIMENTAL
Intervention: Validated proteomic biomarker risk predictor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound dating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excluding dating by LMP
Number of subjects: 0
Study: 35629127

Group type: EXPERIMENTAL
Intervention: Oxygen pulse measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 35629401

Group type: EXPERIMENTAL
Intervention: Symptomatic atherosclerosis
Number of subjects: 509
Study: 35632416

Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 1 year after primary immunization (Group 1)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 2 years after primary immunization (Group 2)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated varicella vaccine (VarV) administered 3 years after primary immunization (Group 3)
Number of subjects: 849
Study: 35632821

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 0
Study: 35633291

Group type: EXPERIMENTAL
Intervention: Sensor-detected hypoglycaemia (SDH) using continuous glucose monitoring (CGM) for 10 weeks
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment via mobile app
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Health economic outcomes assessment
Number of subjects: 600
Study: 35633435

Group type: EXPERIMENTAL
Intervention: Gambling Attitudes and Beliefs Survey (GABS)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: GABS
Number of subjects: 415
Study: 35633970

Group type: EXPERIMENTAL
Intervention: Infusion of autologous thymic-derived regulatory T cells (thyTreg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic immunosuppression
Number of subjects: 0
Study: 35634171

Group type: EXPERIMENTAL
Intervention: IC/IR820 NPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photothermal therapy
Number of subjects: 0
Study: 35634208

Group type: EXPERIMENTAL
Intervention: MST + sham tDCS
Number of subjects: 26

Group type: COMPARATOR
Intervention: MST + tDCS
Number of subjects: 26
Study: 35634390

Group type: EXPERIMENTAL
Intervention: Mixed macronutrient tolerance test (MMTT) containing 56-g palm oil, 59-g sucrose, and 26-g egg white protein
Number of subjects: 0
Study: 35634417

Group type: EXPERIMENTAL
Intervention: 10 g of a dietary multi-ingredient nootropic
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 35634506

Group type: COMPARATOR
Intervention: Irisin serum levels in CMT patients (6.51 ± 2.26 μg/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Irisin serum levels in CMT patients with pathological muscle strength (5.56 ± 1.26 μg/ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of irisin with P1PN
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of irisin with Vitamin D
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irisin levels in women (7.31 ± 2.53 μg/ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of irisin with muscle strength in women
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of irisin with muscle quality in women
Number of subjects: 20
Study: 35635160

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 1406
Study: 35635640

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily until disease progression or unacceptable toxicity
Number of subjects: 12
Study: 35635643

Group type: EXPERIMENTAL
Intervention: 10% weight loss
Number of subjects: 75
Study: 35635644

Group type: EXPERIMENTAL
Intervention: Iodine-containing supplements (ICS)
Number of subjects: 481

Group type: COMPARATOR
Intervention: No iodine-containing supplements (non-users)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Not using an ICS
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Iodised salt use
Number of subjects: 481
Study: 35635728

Group type: EXPERIMENTAL
Intervention: Tiotropium / olodaterol combination treatment
Number of subjects: 0
Study: 35635746

Group type: EXPERIMENTAL
Intervention: Mobile Anxiety Sensitivity Program for Smoking (MASP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nicotine replacement therapy and smartphone-based National Cancer Institute QuitGuide app
Number of subjects: 200
Study: 35635989

Group type: EXPERIMENTAL
Intervention: Instrumented Timed Up and Go Test (TUG) in cLBP group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Instrumented Timed Up and Go Test (TUG) in healthy control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Kinematic parameters during TUG in cLBP group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation of RMQD score with temporal and kinematic parameters in cLBP group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation of NPRS score with temporal and kinematic parameters in cLBP group
Number of subjects: 31
Study: 35636644

Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics using mass spectrometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel approach to establish detection limits based on targeted signal extraction
Number of subjects: 0
Study: 35636648

Group type: EXPERIMENTAL
Intervention: WX-081 (sudapyridine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bedaquiline
Number of subjects: 0
Study: 35636689

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 4666
Study: 35636783

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening programme participants with positive screening test results (false positives, colorectal polyps, or CRC)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Developed patient-reported experience measures (PREMs) if existing measures are not applicable
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Qualitative phenomenological study based on individual interviews
Number of subjects: 843
Study: 35636782

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) during pregnancy
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Standard iron-folic acid supplementation
Number of subjects: 4500
Study: 35636789

Group type: EXPERIMENTAL
Intervention: ctDNA testing using a bespoke ctDNA assay (Signatera)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: ctDNA dynamics
Number of subjects: 1500
Study: 35636792

Group type: EXPERIMENTAL
Intervention: Damage Control Resuscitation (DCR) delivered prehospitally
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prehospital factors
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prehospital and in-hospital complications
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prehospital ultrasound
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Volume of first 24-hours blood product administration
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prehospital blood transfusions
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale Extended
Number of subjects: 500
Study: 35636921

Group type: EXPERIMENTAL
Intervention: Erlotinib 350 mg once weekly for 6 months
Number of subjects: 46
Study: 35637081

Group type: EXPERIMENTAL
Intervention: Prognostic nutritional index (PNI) combined with serum sodium level
Number of subjects: 2882

Group type: EXPERIMENTAL
Intervention: Combination of PNI and serum sodium level
Number of subjects: 2882
Study: 35637506

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Prompt care-seeking behaviour
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Determinants of care-seeking
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Visiting health centres
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Knowledge about malaria
Number of subjects: 1394
Study: 35638924

Group type: EXPERIMENTAL
Intervention: Thoracic aortic wall area (AWA) and prevalent thoracic plaque
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Thoracic aortic wall area (AWA)
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Prevalent thoracic plaque
Number of subjects: 1513
Study: 35638929

Group type: EXPERIMENTAL
Intervention: MRI-based three-dimensional texture analysis of infrapatellar fat pad (IPFP) abnormalities
Number of subjects: 690

Group type: COMPARATOR
Intervention: Control group matched 1:1 with case participants
Number of subjects: 690
Study: 35639023

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35639134

Group type: EXPERIMENTAL
Intervention: RECOVER group (mental disorders)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RECOVER group (mild disease severity, level 1)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RECOVER group (severe mental illness, level 4)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RECOVER group (level 1)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RECOVER group (level 4)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: RECOVER group (levels 2 to 4)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Comparison group (general population without mental disorders)
Number of subjects: 816
Study: 35639137

Group type: EXPERIMENTAL
Intervention: Percutaneous drainage (PD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Endoscopic approach (END)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Internal derivation (INT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Necrosectomy (NE)
Number of subjects: 47
Study: 35639457

Group type: EXPERIMENTAL
Intervention: 20 g daily collagen peptide supplement
Number of subjects: 40
Study: 35639644

Group type: EXPERIMENTAL
Intervention: mRNA (BNT162b2) vaccine
Number of subjects: 164
Study: 35639825

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 1 (n = 8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 2 (n = 4)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 3 (n = 9)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in patients with active BMs (overall)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in patients with measurable intracranial or extracranial lesions at baseline
Number of subjects: 21
Study: 35639922

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment in CARDS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-COVID-19 critically ill controls
Number of subjects: 20